U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164313) titled 'A Study of ZW251 in Participants With Advanced Solid Tumors' on Aug. 27.
Brief Summary: The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC).
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Intervention:
DRUG: ZW251
Administered intravenously
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Zymeworks BC Inc.
Disclaimer: Curated by HT Syndication....